Clinical outcomes of subcutaneous methotrexate in the management of chronic plaque psoriasis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250231Keywords:
Clinical outcomes, Subcutaneous methotrexate, Chronic plaque psoriasisAbstract
Background: Chronic plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis. Subcutaneous methotrexate has been utilized in the management of chronic plaque psoriasis, offering an alternative route of administration to the traditional oral method. The aim of this study was to evaluate the clinical outcomes of subcutaneous methotrexate in the management of chronic plaque psoriasis.
Methods: This cross-sectional observational study was conducted in department of dermatology, Bangabandhu Sheikh Mujib medical university, Dhaka, Bangladesh, during the period from November 2023 to May 2024. Total 70 participants were included in this study.
Results: The average age of participants was 42.3±11.8 years, with 52.9% males and 47.1% females. Baseline PASI scores averaged 18.5±4.2, indicating moderate-to-severe psoriasis. Mean psoriasis duration was 7.2±3.5 years. Depression (34.3%) was the most common comorbidity, followed by diabetes (15.7%) and hypertension (8.6%). Majority of the participants, 62.86% (n=44), had moderate psoriasis. Nausea (58.9%) was the primary reason for switching from oral to subcutaneous methotrexate, which led to progressive PASI reductions: 32.9% at Week 4, 53.0% at week 8, 69.7% at week 12, and 84.9% at week 16 (p<0.001). Adverse events were mild, with nausea (11.4%) and fatigue (8.6%) being most common.
Conclusions: This study demonstrated that subcutaneous methotrexate is a highly effective, safe, and well-tolerated treatment for moderate-to-severe chronic plaque psoriasis.
Metrics
References
Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Academy Dermatol Venereol. 2012;26(s2):3-11. DOI: https://doi.org/10.1111/j.1468-3083.2011.04410.x
Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471. DOI: https://doi.org/10.4103/2229-5178.193906
Bhuiyan MSI, Sikder MS, Mahmud M, Nandy AK, Haque MM. Prevalence of psoriasis in Bangladesh: A community-based survey. J Pak Assoc Dermatologists. 2020;30(1):39-45.
Warren RB, Mrowietz U, Kiedrowski R von, Niesmann J, Wilsmann-Theis D, Ghoreschi K, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2017;389(10068):528-37. DOI: https://doi.org/10.1016/S0140-6736(16)32127-4
Da Silva N, Augustin M, Hilbring C, Braren-von Stülpnagel CC, Sommer R. Psychological (co)morbidity in patients with psoriasis: the impact of pruritus and anogenital involvement on symptoms of depression and anxiety and on body dysmorphic concerns - a cross-sectional study. BMJ Open. 2022;12(9):e055477. DOI: https://doi.org/10.1136/bmjopen-2021-055477
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145-54. DOI: https://doi.org/10.1038/s41584-020-0373-9
Pichlmeier U, Heuer KU. Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate. Clin Exp Rheumatol. 2014;32(4):563-71.
Attwa EM, Elkot RA, Abdelshafey AS, Hafez AR. Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis. Dermatol Ther. 2019;32(5):e13051. DOI: https://doi.org/10.1111/dth.13051
Berger EM, Gottlieb AB. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol. 2007;7(4):434-4. DOI: https://doi.org/10.1016/j.coph.2007.06.002
Bonifati C, Graceffa D, Lora V, Maiani E. Clinical characteristics and systemic therapies administered to first-time patients at a tertiary psoriasis outpatient clinic. Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Societa Ital Dermatologia Sifilografia. 2015;151(6):596-602.
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Academy Dermatol. 2020;82(1):117-22. DOI: https://doi.org/10.1016/j.jaad.2019.08.026
Hoffmann JH, Enk AH. Evaluation of psoriasis area and severity index thresholds as proxies for systemic inflammation on an individual patient level. Dermatology. 2022;238(4):609-14. DOI: https://doi.org/10.1159/000520163
Lajevardi V, Hallaji Z, Daklan S, Abedini R, Goodarzi A, Abdolreza M. The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial. Int J Dermatol. 2015;54(1):95-101. DOI: https://doi.org/10.1111/ijd.12585
Dolan L, Joshi A. AB0498 A True to Life Study on Effects of Switching from Oral to Subcutaneous Methotrexate. Ann Rheumat Dis. 2015;74(2):1065-5. DOI: https://doi.org/10.1136/annrheumdis-2015-eular.1058
Kromann CB, Lage-Hansen PR, Koefoed M, Jemec GBE. Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects? J Dermatolog Treat. 2015;26(2):188-90. DOI: https://doi.org/10.3109/09546634.2014.927817
Nakarmi S, Pudasaini K, Adhikari B, Vaidya B. Adverse Events Profile of Low-dose Methotrexate in Nepalese Patients with Rheumatoid Arthritis: an Observational Study. J Nepal Health Res Council. 2020;18(3):360-5. DOI: https://doi.org/10.33314/jnhrc.v18i3.2743
Schiff MH, Jaffe JS, Freundlich B. Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann Rheumatic Dis. 2014;73(8):1549-51. DOI: https://doi.org/10.1136/annrheumdis-2014-205228
Houghton K, Patil D, Gomez B, Feldman SR. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab. Dermatol Ther (Heidelb). 2021;11(4):1373-84. DOI: https://doi.org/10.1007/s13555-021-00564-2
Khadka DK, Agrawal S, Dhali TK. Methotrexate plus narrow band ultraviolet B (NBUVB) versus methotrexate alone in the treatment of moderate to severe plaque psoriasis: A randomized clinical trial. Nep J Dermatol Venereol Leprol. 2015;13(1):12-23. DOI: https://doi.org/10.3126/njdvl.v13i1.14298
Downloads
Published
How to Cite
Issue
Section
